These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17353899)

  • 1. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
    Brien G; Trescol-Biemont MC; Bonnefoy-Bérard N
    Oncogene; 2007 Aug; 26(39):5828-32. PubMed ID: 17353899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
    Olsson A; Norberg M; Okvist A; Derkow K; Choudhury A; Tobin G; Celsing F; Osterborg A; Rosenquist R; Jondal M; Osorio LM
    Br J Cancer; 2007 Sep; 97(6):769-77. PubMed ID: 17726463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
    Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of peptide aptamers targeting Bfl-1 anti-apoptotic protein.
    Brien G; Debaud AL; Bickle M; Trescol-Biemont MC; Moncorge O; Colas P; Bonnefoy-Berard N
    Biochemistry; 2011 Jun; 50(23):5120-9. PubMed ID: 21563784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
    Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
    Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis.
    Xia L; Wurmbach E; Waxman S; Jing Y
    Leukemia; 2006 Jun; 20(6):1009-16. PubMed ID: 16572199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S; Ng CP; Bonavida B
    Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
    Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
    Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
    Hussain SR; Cheney CM; Johnson AJ; Lin TS; Grever MR; Caligiuri MA; Lucas DM; Byrd JC
    Clin Cancer Res; 2007 Apr; 13(7):2144-50. PubMed ID: 17404098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.
    Tarte K; Jourdan M; Veyrune JL; Berberich I; Fiol G; Redal N; Shaughnessy J; Klein B
    Br J Haematol; 2004 May; 125(3):373-82. PubMed ID: 15086420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Smith MR; Jin F; Joshi I
    Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.